$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

$acad Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023004757 Filed on February 28, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022 Q1
Revenue	$118.5M	$136.5M	$115.5M
YoY Change	2.59%	4.38%	8.37%
Cost Of Revenue	$1.667M	$2.413M	$2.950M
YoY Change	-43.49%	-5.78%	35.01%
Gross Profit	$116.8M	$134.1M	$112.5M
YoY Change	3.8%	4.49%	7.81%
Gross Profit Margin	98.59%	98.23%	97.45%
Selling, General & Admin	$101.2M	$104.4M	$96.68M
YoY Change	4.71%	-1.43%	-13.42%
% of Gross Profit	86.68%	77.87%	85.92%
Research & Development	$69.14M	$75.74M	$128.9M
YoY Change	-46.34%	13.14%	126.17%
% of Gross Profit	59.2%	56.49%	114.52%
Depreciation & Amortization	$426.0K	$489.0K	$516.0K
YoY Change	-17.44%	-8.6%	-1.71%
% of Gross Profit	0.36%	0.36%	0.46%
Operating Expenses	$170.4M	$180.1M	$225.5M
YoY Change	-24.46%	4.22%	33.74%
Operating Profit	-$53.58M	-$46.06M	-$113.0M
YoY Change	-52.59%	3.42%	69.26%
Interest Expense	$3.800M	$3.630M	$105.0K
YoY Change	3519.05%	2713.95%	-47.5%
% of Operating Profit
Other Income/Expense, Net	$4.845M	$1.543M	$340.0K
YoY Change	1325.0%	-4.93%	-334.48%
Pretax Income	-$44.90M	-$40.89M	-$112.6M
YoY Change	-60.11%	-4.7%	69.47%
Income Tax	-$1.900M	$835.0K	$485.0K
% Of Pretax Income
Net Earnings	-$43.02M	-$41.73M	-$113.1M
YoY Change	-61.95%	-3.18%	70.14%
Net Earnings / Revenue	-36.32%	-30.57%	-97.91%
Basic Earnings Per Share	-$0.27	-$0.26	-$0.70
Diluted Earnings Per Share	-$0.27	-$0.26	-$701.2K
COMMON SHARES
Basic Shares Outstanding	162.2M	161.9M	161.2M
Diluted Shares Outstanding	162.3M		161.2M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$402.9M	$416.8M	$446.0M
YoY Change	-9.67%	-19.95%	-22.81%
Cash & Equivalents	$290.9M	$114.8M	$204.9M
Short-Term Investments	$112.0M	$302.0M	$241.1M
Other Short-Term Assets	$23.63M	$21.40M	$25.76M
YoY Change	-8.24%	-10.44%	-9.63%
Inventory	$11.02M	$11.56M	$13.21M
Prepaid Expenses	$23.63M	$21.40M	$25.76M
Receivables	$65.92M	$62.20M	$62.71M
Other Receivables	$4.335M	$885.0K	$769.0K
Total Short-Term Assets	$502.9M	$507.9M	$542.2M
YoY Change	-7.26%	-17.79%	-19.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.595M	$6.021M	$7.531M
YoY Change	-25.71%	-25.18%	-89.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$12.43M	$7.587M	$4.336M
YoY Change	186.72%	89.82%	-42.95%
Total Long-Term Assets	$152.5M	$79.88M	$82.03M
YoY Change	85.86%	-2.95%	1.02%
TOTAL ASSETS
Total Short-Term Assets	$502.9M	$507.9M	$542.2M
Total Long-Term Assets	$152.5M	$79.88M	$82.03M
Total Assets	$655.3M	$587.8M	$624.3M
YoY Change	4.97%	-16.04%	-17.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.42M	$12.75M	$10.77M
YoY Change	61.79%	85.37%	22.36%
Accrued Expenses	$206.9M	$112.9M	$108.8M
YoY Change	90.08%	26.56%	8.27%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$224.3M	$125.6M	$119.6M
YoY Change	87.54%	30.77%	9.33%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.305M	$9.074M	$4.373M
YoY Change	21.31%	29.0%	-93.19%
Total Long-Term Liabilities	$5.305M	$9.074M	$4.373M
YoY Change	21.31%	29.0%	-93.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$224.3M	$125.6M	$119.6M
Total Long-Term Liabilities	$5.305M	$9.074M	$4.373M
Total Liabilities	$281.0M	$187.4M	$179.5M
YoY Change	56.61%	17.69%	3.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.413B	-$2.370B	-$2.267B
YoY Change	6.44%	10.03%
Common Stock	$2.787B	$2.771B	$2.712B
YoY Change	2.77%	2.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$374.3M	$400.4M	$444.8M
YoY Change
Total Liabilities & Shareholders Equity	$655.3M	$587.8M	$624.3M
YoY Change	4.97%	-16.04%	-17.34%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022 Q1
OPERATING ACTIVITIES
Net Income	-$43.02M	-$41.73M	-$113.1M
YoY Change	-61.95%	-3.18%	70.14%
Depreciation, Depletion And Amortization	$426.0K	$489.0K	$516.0K
YoY Change	-17.44%	-8.6%	-1.71%
Cash From Operating Activities	-$17.93M	-$23.85M	-$76.33M
YoY Change	-76.51%	3.17%	26.9%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$192.5M	-$17.75M	$131.3M
YoY Change	46.57%	-124.81%	311.1%
Cash From Investing Activities	$192.5M	-$17.75M	$131.3M
YoY Change	46.57%	-124.81%	325.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$2.467M
YoY Change			-68.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.466M	1.614M	2.467M
YoY Change	-40.58%	-63.02%	-68.07%
NET CHANGE
Cash From Operating Activities	-17.93M	-23.85M	-76.33M
Cash From Investing Activities	192.5M	-17.75M	131.3M
Cash From Financing Activities	1.466M	1.614M	2.467M
Net Change In Cash	176.0M	-39.99M	57.49M
YoY Change	206.25%	-175.74%	-366.86%
FREE CASH FLOW
Cash From Operating Activities	-$17.93M	-$23.85M	-$76.33M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$23.85M	-$76.33M
YoY Change		3.18%	24.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2020	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2021	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2021	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001070494
CY2020	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	4924000
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-50768
CY2022	dei	Entity Registrant Name EntityRegistrantName	ACADIA PHARMACEUTICALS INC
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1376651
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	12830 El Camino Real
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2022	dei	City Area Code CityAreaCode	858
CY2022	dei	Local Phone Number LocalPhoneNumber	558-2871
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	ACAD
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1700000000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	162230184
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	California
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114846000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147435000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	301977000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	373271000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	62195000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	64366000
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	885000
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	978000
CY2022Q4	acad	Short Term Inventory ShortTermInventory	6636000
CY2021Q4	acad	Short Term Inventory ShortTermInventory	7881000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	21398000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	23892000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	507937000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	617823000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6021000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8047000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	55573000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	58268000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2021Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	6217000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7587000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3997000
CY2022Q4	us-gaap	Assets Assets	587812000
CY2021Q4	us-gaap	Assets Assets	700122000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12746000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6876000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	112884000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89192000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	125630000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	96068000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	52695000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	56126000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9074000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7034000
CY2022Q4	us-gaap	Liabilities Liabilities	187399000
CY2021Q4	us-gaap	Liabilities Liabilities	159228000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	162064872
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	162064872
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	161012695
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161012695
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	16000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	16000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2770923000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2694646000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2369551000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2153576000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-975000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-192000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	400413000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	540894000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	587812000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	700122000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	517235000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	484145000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	441755000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	517235000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	484145000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	441755000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10166000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10843000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10211000
CY2022	acad	License Fees And Royalty Expense LicenseFeesAndRoyaltyExpense	0
CY2021	acad	License Fees And Royalty Expense LicenseFeesAndRoyaltyExpense	8298000
CY2020	acad	License Fees And Royalty Expense LicenseFeesAndRoyaltyExpense	10339000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	361575000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	239415000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	319130000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	369090000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	396028000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	388661000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	740831000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	654584000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	728341000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-223596000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-170439000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-286586000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6610000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	591000
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6610000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3542000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2329000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-997000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-213444000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-167519000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-280973000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2531000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	351000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	611000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-215975000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167870000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-281584000
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.79
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.79
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	161683
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	161683
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	160493
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	160493
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	157331
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	157331
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-215975000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167870000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-281584000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-789000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-235000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-253000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	6000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-216758000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-168098000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-281845000
CY2022	us-gaap	Profit Loss ProfitLoss	-215975000
CY2021	us-gaap	Profit Loss ProfitLoss	-167870000
CY2020	us-gaap	Profit Loss ProfitLoss	-281584000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	68201000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	63615000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	84422000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2736000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2404000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1470000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1108000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1477000
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	3542000
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	2329000
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	-997000
CY2022	us-gaap	Depreciation Depreciation	2026000
CY2021	us-gaap	Depreciation Depreciation	2236000
CY2020	us-gaap	Depreciation Depreciation	1455000
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-281000
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	44280000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2171000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16119000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12466000
CY2022	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-93000
CY2021	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-1057000
CY2020	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-58000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2415000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4210000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3320000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2494000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1802000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7088000
CY2022	acad	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-6566000
CY2021	acad	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-6287000
CY2020	acad	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-4280000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	48000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-10000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-182000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5870000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1617000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1271000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	24306000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8455000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	27569000
CY2022	acad	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-7916000
CY2021	acad	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-5433000
CY2020	acad	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1769000
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2040000
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1854000
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2319000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-114035000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-125660000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-136166000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	363174000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	492797000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	339908000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	436415000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	422817000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	540004000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1122000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7587000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	73241000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-71102000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	192509000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8199000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18162000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	80996000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8199000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18162000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80996000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-8000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-32589000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-178593000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	137331000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153205000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	331798000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	194467000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	120616000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153205000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	331798000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2190000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1038000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1113000
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	130000
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	44280000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	699135000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	44280000
CY2020	acad	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	73834000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7162000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-281584000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	84443000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-261000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627009000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12850000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5312000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167870000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	63821000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-228000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	540894000
CY2022	acad	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	3705000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4494000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-215975000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	68078000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-783000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	400413000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</span></p>
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147435000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114846000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	326028000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147435000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5770000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153205000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	120616000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	331798000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153205000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	600000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	1300000
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	400000
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2016Q2	acad	Regulatory Milestone Payment RegulatoryMilestonePayment	8000000.0
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8000000.0
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	5500000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	1800000
CY2020	us-gaap	Advertising Expense AdvertisingExpense	51100000
CY2022Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	0
CY2021Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	0
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentration Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash, cash equivalents, investment securities, accounts receivable, and restricted cash. The Company invests its excess cash primarily in money market funds, U.S. treasury notes, and high quality, marketable debt instruments of corporations and government sponsored enterprises in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. All investment securities have a credit rating of at least Aa3/AA- or better, or P-1/A-1 or better, as determined by Moody’s Investors Service or Standard & Poor’s. Further, the Company specifies credit quality standards for its customers that are designed to limit the Company’s credit exposure to any single party.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company does not currently have any of its own manufacturing facilities, and therefore it depends on an outsourced manufacturing strategy for the production of NUPLAZID for commercial use and for the production of its product candidates for clinical trials. The Company has contracts in place with two third-party manufacturers of commercial drug product and one third-party manufacturer of drug substance that is approved for the production of NUPLAZID API. Although there are potential sources of supply other than the Company’s existing suppliers, any new supplier would be required to qualify under applicable regulatory requirements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company has entered into distribution agreements with a limited number of SPs and SDs, and all of the Company’s product sales are to these customers. For the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company’s </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> largest customers represented approximately </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">73</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">of the Company’s product revenue and </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">74</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the Company’s accounts receivable balance at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2022. For the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company’s </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> largest customers represented approximately </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">74</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the Company’s product revenue and </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">77</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the Company’s accounts receivable balance at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2021. For the year ended December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, the Company’s </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> largest customers represented approximately </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">74</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the Company’s product revenue and </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">% of the Company’s accounts receivable balance at December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">.</span></p>
CY2022	acad	Number Of Large Customers NumberOfLargeCustomers	4
CY2021	acad	Number Of Large Customers NumberOfLargeCustomers	4
CY2020	acad	Number Of Large Customers NumberOfLargeCustomers	4
CY2022	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0
CY2021	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	6800000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	68201000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	63615000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	84422000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21185000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17535000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19331000
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022Q4	acad	Debt Securities And Equity Securities Fv Ni Amortized Cost DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost	302968000
CY2022Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Gains DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains	46000
CY2022Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Losses DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses	1037000
CY2022Q4	acad	Debt Securities And Equity Securities Fv Ni DebtSecuritiesAndEquitySecuritiesFvNi	301977000
CY2021Q4	acad	Debt Securities And Equity Securities Fv Ni Amortized Cost DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost	373475000
CY2021Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Gains DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains	9000
CY2021Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Losses DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses	213000
CY2021Q4	acad	Debt Securities And Equity Securities Fv Ni DebtSecuritiesAndEquitySecuritiesFvNi	373271000
CY2022	acad	Available For Sale Investment Securities Contractual Maturity Dates AvailableForSaleInvestmentSecuritiesContractualMaturityDates	less than one year
CY2021	acad	Available For Sale Investment Securities Contractual Maturity Dates AvailableForSaleInvestmentSecuritiesContractualMaturityDates	less than one year
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	43
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	39
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	230174000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1037000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	230174000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1037000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	290997000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	213000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	290997000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	213000
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	395597000
CY2022Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	898000
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	499785000
CY2021Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	603000
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	603000
CY2022	acad	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Vesting Of Awards FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityVestingOfAwards	1798000
CY2022	acad	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Expense Forfeited FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExpenseForfeited	-117000
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-1386000
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	898000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1926000
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1114000
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4427000
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6767000
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5207000
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6217000
CY2022Q4	us-gaap	Inventory Net InventoryNet	11560000
CY2021Q4	us-gaap	Inventory Net InventoryNet	14098000
CY2022Q4	acad	Short Term Inventory ShortTermInventory	6636000
CY2021Q4	acad	Short Term Inventory ShortTermInventory	7881000
CY2022Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	4924000
CY2021Q4	us-gaap	Inventory For Long Term Contracts Or Programs InventoryForLongTermContractsOrPrograms	6217000
CY2022Q4	us-gaap	Inventory Net InventoryNet	11560000
CY2021Q4	us-gaap	Inventory Net InventoryNet	14098000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14118000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14231000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8097000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6184000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6021000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8047000
CY2022	us-gaap	Depreciation Depreciation	2000000.0
CY2021	us-gaap	Depreciation Depreciation	2200000
CY2020	us-gaap	Depreciation Depreciation	1500000
CY2022	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	100000
CY2021	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0
CY2020	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	3100000
CY2022Q4	acad	Accrued Clinical Development Services Current AccruedClinicalDevelopmentServicesCurrent	35048000
CY2021Q4	acad	Accrued Clinical Development Services Current AccruedClinicalDevelopmentServicesCurrent	27270000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	28023000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	25896000
CY2022Q4	acad	Accrued Sales Allowances Current AccruedSalesAllowancesCurrent	26046000
CY2021Q4	acad	Accrued Sales Allowances Current AccruedSalesAllowancesCurrent	15717000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	11377000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	9319000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9305000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8304000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3085000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2686000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	112884000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89192000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15086141
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.58
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3393568
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	22.79
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	226943
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	16.32
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1913301
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	32.68
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16339465
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.83
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1052000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	11386596
CY2022Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice	30.70
CY2022	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm1	P4Y6M
CY2022Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Intrinsic Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue1	725000
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4952869
CY2022Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageExercisePrice	27.82
CY2022	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm1	P8Y3M18D
CY2022Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Intrinsic Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue1	327000
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	15.92
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1700000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8000000.0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	55500000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3700000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12900000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.66
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	24.07
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	24.16
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	63900000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	66000000.0
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	PSUs for which the number of shares issuable at the end of performance period can reach up to 200% of the shares approved in the award based on the achievement of certain pre-defined Acadia-specific performance criteria and continued employment through the vesting period
CY2021Q4	us-gaap	Banking Regulation Maximum Payout Amount BankingRegulationMaximumPayoutAmount	15100000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	4400000
CY2022	us-gaap	Banking Regulation Maximum Payout Amount BankingRegulationMaximumPayoutAmount	11800000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	1800000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	5600000
CY2022	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	900000
CY2021	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	600000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	300000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	600000
CY2022	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.60
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	5100000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	5800000
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	5100000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-233216000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-138913000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-238885000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	19772000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-28606000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-42088000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-213444000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-167519000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-280973000
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	2500000
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	400000
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	400000
CY2020	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	200000
CY2022Q4	acad	Federal Research And Development Credit Carryforwards FederalResearchAndDevelopmentCreditCarryforwards	74200000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	225993000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	229476000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	83074000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	74702000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	51661000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	51170000
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	42677000
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	41355000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	38507000
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	24030000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6741000
CY2022Q4	acad	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	14730000
CY2021Q4	acad	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	15550000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13770000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11700000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	494442000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	430694000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	481210000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	416630000
CY2022Q4	acad	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	13203000
CY2021Q4	acad	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	14063000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	29000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	13232000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	14064000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	64600000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-44823000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-35179000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-59004000
CY2022	acad	Income Tax Expense Permanent Tax Differences IncomeTaxExpensePermanentTaxDifferences	9050000
CY2021	acad	Income Tax Expense Permanent Tax Differences IncomeTaxExpensePermanentTaxDifferences	6696000
CY2020	acad	Income Tax Expense Permanent Tax Differences IncomeTaxExpensePermanentTaxDifferences	991000
CY2022	acad	Income Tax Expenses Write Off Of Iprd IncomeTaxExpensesWriteOffOfIPRD	2449000
CY2021	acad	Income Tax Expenses Write Off Of Iprd IncomeTaxExpensesWriteOffOfIPRD	1277000
CY2020	acad	Income Tax Expenses Write Off Of Iprd IncomeTaxExpensesWriteOffOfIPRD	9565000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-9974000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-11727000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-17909000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11227000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	36099000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5925000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2232000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2617000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-5038000
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	6993000
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	3879000
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	2665000
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1971000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	2857000
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	4208000
CY2022	acad	Income Tax Reconciliation Limitation On Executive Compensation IncomeTaxReconciliationLimitationOnExecutiveCompensation	3918000
CY2021	acad	Income Tax Reconciliation Limitation On Executive Compensation IncomeTaxReconciliationLimitationOnExecutiveCompensation	1808000
CY2020	acad	Income Tax Reconciliation Limitation On Executive Compensation IncomeTaxReconciliationLimitationOnExecutiveCompensation	3705000
CY2022	acad	Income Tax Reconciliation Deferred Rate Adjustment IncomeTaxReconciliationDeferredRateAdjustment	922000
CY2021	acad	Income Tax Reconciliation Deferred Rate Adjustment IncomeTaxReconciliationDeferredRateAdjustment	-2424000
CY2020	acad	Income Tax Reconciliation Deferred Rate Adjustment IncomeTaxReconciliationDeferredRateAdjustment	2130000
CY2022	acad	Income Tax Reconciliation Switzerland Tax Reform IncomeTaxReconciliationSwitzerlandTaxReform	0
CY2021	acad	Income Tax Reconciliation Switzerland Tax Reform IncomeTaxReconciliationSwitzerlandTaxReform	-923000
CY2020	acad	Income Tax Reconciliation Switzerland Tax Reform IncomeTaxReconciliationSwitzerlandTaxReform	53045000
CY2022	acad	Effective Income Tax Rate Reconciliation Expiration Of Attributes Amount EffectiveIncomeTaxRateReconciliationExpirationOfAttributesAmount	16142000
CY2021	acad	Effective Income Tax Rate Reconciliation Expiration Of Attributes Amount EffectiveIncomeTaxRateReconciliationExpirationOfAttributesAmount	0
CY2020	acad	Effective Income Tax Rate Reconciliation Expiration Of Attributes Amount EffectiveIncomeTaxRateReconciliationExpirationOfAttributesAmount	0
CY2022Q4	acad	Gilti Gilti	10804000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-26000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	605000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	328000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2531000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	351000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	611000
CY2022	acad	Unrecognized Tax Benefits Increases Resulting From Current And Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentAndPriorPeriodTaxPositions	5100000
CY2021	acad	Unrecognized Tax Benefits Increases Resulting From Current And Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentAndPriorPeriodTaxPositions	4100000
CY2020	acad	Unrecognized Tax Benefits Increases Resulting From Current And Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentAndPriorPeriodTaxPositions	2900000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1200000
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13923000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9843000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6945000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5140000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3973000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2722000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	38000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	140000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	212000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	37000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	33000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	36000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	19064000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13923000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9843000
CY2022	acad	Lease Expiration Month And Year LeaseExpirationMonthAndYear	2031-02
CY2022	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company leases facilities and certain equipment under noncancelable operating leases with remaining lease terms of 1.0 year to 8.4 years, some of which include options to extend the lease for up to two five-year terms.
CY2022	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	some of which include options to extend the lease for up to two five-year terms.
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8095000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	8874000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	6917000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	9083000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	5303000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3871000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	17272000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9305000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8304000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	52695000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	56126000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	62000000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	64430000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9562000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9112000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	9192000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8556000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	8282000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	28687000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	73391000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11391000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	62000000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y10M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.044
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.043
CY2020Q3	acad	Capitalization Of Lease Liability CapitalizationOfLeaseLiability	40300000
CY2021Q1	acad	Capitalization Of Lease Liability CapitalizationOfLeaseLiability	19200000
CY2022Q1	us-gaap	Revenues Revenues	115468000
CY2022Q2	us-gaap	Revenues Revenues	134563000
CY2022Q3	us-gaap	Revenues Revenues	130714000
CY2022Q4	us-gaap	Revenues Revenues	136490000
CY2022	us-gaap	Revenues Revenues	517235000
CY2022Q1	us-gaap	Gross Profit GrossProfit	112518000
CY2022Q2	us-gaap	Gross Profit GrossProfit	131896000
CY2022Q3	us-gaap	Gross Profit GrossProfit	128578000
CY2022Q4	us-gaap	Gross Profit GrossProfit	134076000
CY2022	us-gaap	Gross Profit GrossProfit	507068000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-113056000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-34011000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-27183000
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-41725000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-215975000
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.70
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
CY2021Q1	us-gaap	Revenues Revenues	106554000
CY2021Q2	us-gaap	Revenues Revenues	115221000
CY2021Q3	us-gaap	Revenues Revenues	131612000
CY2021Q4	us-gaap	Revenues Revenues	130758000
CY2021	us-gaap	Revenues Revenues	484145000
CY2021Q1	us-gaap	Gross Profit GrossProfit	104369000
CY2021Q2	us-gaap	Gross Profit GrossProfit	112695000
CY2021Q3	us-gaap	Gross Profit GrossProfit	127924000
CY2021Q4	us-gaap	Gross Profit GrossProfit	128314000
CY2021	us-gaap	Gross Profit GrossProfit	473302000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-66448000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-43871000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14457000
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-43094000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167870000
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05

Files In Submission

Name	View Source	Status
0000950170-23-004757-index-headers.html	Edgar Link	pending
0000950170-23-004757-index.html	Edgar Link	pending
0000950170-23-004757.txt	Edgar Link	pending
0000950170-23-004757-xbrl.zip	Edgar Link	pending
acad-20221231.htm	Edgar Link	pending
acad-20221231.xsd	Edgar Link	pending
acad-ex10_12.htm	Edgar Link	pending
acad-ex10_33.htm	Edgar Link	pending
acad-ex21_1.htm	Edgar Link	pending
acad-ex23_1.htm	Edgar Link	pending
acad-ex31_1.htm	Edgar Link	pending
acad-ex31_2.htm	Edgar Link	pending
acad-ex32_1.htm	Edgar Link	pending
acad-ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img166113560_0.jpg	Edgar Link	pending
img235382597_0.jpg	Edgar Link	pending
img235382597_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
acad-20221231_cal.xml	Edgar Link	unprocessable
acad-20221231_def.xml	Edgar Link	unprocessable
acad-20221231_lab.xml	Edgar Link	unprocessable
acad-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
acad-20221231_htm.xml	Edgar Link	completed
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

2023 Q1 Form 10-K Financial Statement

#000095017023004757 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD ACADIA PHARMACEUTICALS INC Stock $acad

2023 Q1 Form 10-K Financial Statement

#000095017023004757 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad